Cryopreservation of hematopoietic stem cells (HSCs) has been a standard of care at many centers. It is technically demanding, expensive and limits the ability of many hematology centers to perform such procedures in resource constrained scenario. Recently, Journal has published two articles that question the long-standing practice of cryopreservation of HSCs. Kardduss-Urueta et al. [1] in a large multicenter trial showed that cryopreservation of HSCs is not required. They also did not find any correlation between numbers of storage days at 4°C and viability after storage or rates of recovery of neutrophils or platelets.
Another study has in fact demonstrated that noncryopreserved stem cells are superior to cryopreserved stem cells with faster engraftment, lower incidence of febrile neutropenia and shorter hospital stay after the transplantation procedure [2] .
Hematopoietic stem cells remain viable for several days at 4°C storage [3, 4] . Studies with non-cryopreserved HSCs are limited [1, 2, [5] [6] [7] [8] . In support of these, we report the outcome of ASCT in MM and lymphoma with mobilized non-cryopreserved peripheral blood stem cell (PBSC) graft in 76 patients in terms of feasibility, safety, and efficacy.
Informed written consent was obtained from all patients. Peripheral blood stem cell apheresis was performed using Hemonetics MCS plus or Cobe Spectra apheresis machine. The harvested stem cells were stored in a conventional blood bank refrigerator at 4°C. Stem cell yield of the harvest was determined by CD 34 cell enumeration using ISHAGE protocol [9] . The goal of apheresis was to collect an average of 2 × 10 6 /kg CD 34 stem cells. A second harvest was not attempted if dose was 2 × 10 6 /kg CD 34 stem cells or more due to financial reasons. Patients received G-CSF 300 micrograms once a day starting on Day +6 after infusion of stem cells until the time of engraftment. Length of hospital stay was defined as the time from the day of infusion of stem cell product to the day of hospital discharge. Transplant related mortality (TRM) was taken as death from any cause other than disease relapse or progression occurring within the first 100 days after autologous hematopoietic stem cell transplant (ASCT). Patients receiving ASCT where cryopreserved HSCs were used were excluded.
General patient characteristics are outlined in Table 1 . Transplant characteristics are shown in Table 2 . Nine patients with multiple myeloma and five patients with lymphoma had CD 34 dose <2 million/kg (Table 1) . Febrile neutropenia was seen in 58 out of 59 myeloma patients and 14 out of 17 lymphoma patients. Mucositis was seen in all patients after high dose chemotherapy with majority developing grade III or IV mucositis. Day 30 TRM in myeloma was nil. One dialysis dependent patient died on day 37 after primary graft failure taking our Day 100 mortality to 2.7%. His blood culture grew methicillin resistant staphylococcus aureus, E. coli and Providencia rettgeri in blood at different times during transplantation. Day 30 mortality for lymphoma was 2 out of 17 during neutropenic phase. One patient had severe reaction to BCNU and subsequently died on Day +8 due to multidrug resistant pseudomonas aeruginosa. Another patient succumbed to febrile neutropenia on Day +9 without engraftment. No cause was identified.
High dose melphalan has very short elimination half-life with predominant renal excretion [10] . This makes an attractive case for not cryopreserving hematopoietic stem cells as they remain viable in this setting. This, however, does call for rigorous scheduling of transplant. In patients with multiple myeloma, whole process (collection of stem cells, administration of high dose melphalan in same evening and hematopoietic stem cell infusion the next day) is at times completed within 36 h. In 5 patients with multiple myeloma who underwent tandem autologous transplant at our center, we cryopreserved HSCs only for II transplant while first one was still stored at 4°C.
A consensus published by the American Society for Blood and Marrow Transplantation recommends collecting a minimum dose of 2 × 10 6 CD 34 + cells/kg to perform ASCT, but the decision to accept collections of between 1 × 10 6 and 2 × 10 6 CD 34 + cells/kg can be individualized according to the circumstances of each patient [11] . These guidelines pertain to cryopreserved stem cell dose. Sarmiento et al. [2] have already demonstrated superiority of non-cryopreserved HSCs over cryopreserved HSCs. Our 14 patients were admitted to transplant unit with HSC dose <2 million/kg. All these 14 patients engrafted in reasonable time frame. There was no difference in engraftment kinetics between patients having <2 million/kg or >2 million/kg stem cell dose. This small data may suggest that for noncryopreserved hematopoietic stem cell smaller dose may be sufficient. This may enable many more patients eligible for HSCT. We are not discussing progression free survival and other outcomes as these are not dependent if HSCs were cryopreserved or not and actually depend on multiple clinical variables. All except three patients in our study engrafted. This proves that HSC viability was not an issue at all. Main limitation of our data as with previous studies is retrospective nature of analysis. We did not measure CD 34 counts after storage and pre-storage counts were taken as measure of viable counts.
The overall cost of an ASCT at our center is~USD 9200. Cost of cryopreservation at our center is US$ 700 per stem cell storage. If a patient requires more apheresis due to poor CD 34 counts then cost of cryopreservation goes up accordingly. Conventional storage is devoid of any toxic side effects that are described with DMSO and cuts down the cost of transplantation. It is high time that official bodies like EBMT state in their guidelines that non-cryopreserved stem cells are safe for use. Overall, with conventional approach, many more hematological centers across the world can start the stem cell transplantation program with transplants for myeloma where they do not need to have costly and technically demanding cryopreservation facility.
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